Chemicals and intermediates used in pharmaceutical manufacturing and drug development.
chemXplore tracks 136 projects in pharma, of which 37 are active.
20 new construction, 16 expansion, and 1 revamp / retrofit.
3 of the active projects carry no start-up date yet.
Owners and developers: Evonik Industries AG (4), Lilly (3), Merck (3), Novo Nordisk (3), Eli Lilly and Company (2), Genentech, Inc. (2)
Investors: Eli Lilly and Company (2), European Investment Bank (2), Evonik Industries AG (2), Takeda (2), AGC Group (1), Clariant AG (1)
Contractors, licensors, and offtakers are recorded on 13 of these 37 projects For subscribers
Targeting: Orforglipron (5), Retatrutide (2), Coagulation factor IX (1), Fumed Silica (1), Glucagon-like peptide-1 (1), Isobutene (1)
Long-acting cabotegravir + rilpivirine achieved superior viral suppression versus standard oral ART at six months when initiated in people with detectable HIV.
Yokohama technical center began cell therapy process development in July 2025 and has been awarded multiple exosome and T‑cell projects, including a program transferred from Milan.
Phase 3 trial of subcutaneous T‑cell‑engaging bispecific with R‑CHOP cut progression/death risk by 51% in newly diagnosed DLBCL (IPI 2–5); safety consistent with known profiles.
EBGLYSS shows durable control, less maintenance dosing and reduced topical use; TOGETHER‑PsO biomarker data assess Taltz+Zepbound vs Taltz; Olumiant pediatric alopecia areata results also included.
New polymethacrylate excipients aim to keep solubility and delayed‑release performance while meeting OECD biodegradability criteria; lab‑scale material available for partner projects.
Adherent culture plate with high oxygen permeability, enhanced surface treatment, low autofluorescence and low drug adsorption to improve organoid culture and screening.
Rina‑S 120 mg/m² Q3W achieved 45.9% ORR and 12.1‑month median DOR in 109 platinum‑resistant ovarian cancer patients; activity seen across FRα expression levels.
Oral ICOTYDE maintains durable skin clearance through Week 112 and yields high site‑specific clearance rates for scalp, genital, hand/foot and nails.
FDA clears pirtobrutinib for newly diagnosed CLL/SLL patients without 17p deletion after BRUIN CLL-313 showed a large PFS benefit versus bendamustine–rituximab.
FDA review remains ongoing; extension caused by facility remediation, not clinical deficiencies. Novo still targets a US launch in H1 2027 and says 2026 outlook is unaffected.
By country, the most active first. active / all projects
The 8 with the most active projects, of 26 countries.
